Christopher Rovaldi
Geschäftsführer bei KEROS THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Christopher Rovaldi ist SVP-Program Management & Operations bei Acceleron Pharma, Inc. Herr Rovaldi war zuvor als Director-Project Management bei Idenix Pharmaceuticals LLC, als Senior Research Associate bei Periodontix, Inc. und als Director-Project Management bei Cubist Pharmaceuticals LLC tätig. Er erhielt einen Graduiertenabschluss und einen Bachelor-Abschluss von der University of New Hampshire.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 31.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Christopher Rovaldi
Unternehmen | Position | Beginn |
---|---|---|
KEROS THERAPEUTICS, INC. | Geschäftsführer | 01.02.2022 |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The company is based in Paramus, NJ. | Präsident | 01.05.2019 |
Ehemalige bekannte Positionen von Christopher Rovaldi
Unternehmen | Position | Ende |
---|---|---|
ACCELERON PHARMA INC. | Geschäftsführer | 01.05.2018 |
IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2007 |
CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2004 |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Corporate Officer/Principal | - |
Ausbildung von Christopher Rovaldi
University of New Hampshire | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The company is based in Paramus, NJ. | Health Technology |